阿替利珠单抗联合卡铂依托泊苷治疗广泛期小细胞肺癌的安全性与患者报告结局:IMpower133随机I/III期试验
IMpower133研究评估阿替利珠单抗联合卡铂依托泊苷(CP/ET)治疗广泛期小细胞肺癌(ES-SCLC)的安全性与患者报告结局。诱导期394例、维持期318例可评估安全性,两阶段不良事件频率组间相似,免疫相关不良事件在阿替利珠单抗组更常见,患者报告的功能与健康相关生活质量在两组均改善且阿替利珠单抗组更明显持久。
要点
- 阿替利珠单抗联合CP/ET总体安全性特征与安慰剂联合CP/ET相当。
- 免疫相关不良事件在阿替利珠单抗组更常见,最常见为皮疹和甲状腺功能减退。
- 患者报告的功能与健康相关生活质量在阿替利珠单抗组改善更明显且更持久。
核心结论
- 在ES-SCLC患者中,阿替利珠单抗联合CP/ET的安全性特征与安慰剂联合CP/ET相当,且未对患者报告的健康相关生活质量产生不利影响。
- 这些数据证明一线阿替利珠单抗联合CP/ET在ES-SCLC中具有正向获益-风险特征,并进一步支持该方案作为该领域新的标准治疗。
研究设计与样本
- IMpower133研究(NCT02763579)为随机I/III期试验,患者接受4个21天周期CP/ET联合静脉阿替利珠单抗1200 mg或安慰剂(诱导期),随后阿替利珠单抗或安慰剂维持治疗直至进展或失去获益。
- 诱导期394例患者可评估安全性,维持期318例可评估安全性。
- 治疗期间每3周使用EORTC QLQ-C30和QLQ-LC13评估患者报告结局。
主要发现
- 两阶段不良事件、3-4级不良事件和严重不良事件的频率组间相似。
- 诱导期免疫相关不良事件在阿替利珠单抗组更常见(28% vs 17%),导致阿替利珠单抗/安慰剂中断9% vs 5%,导致退出4% vs 0%。
- 维持期免疫相关不良事件在阿替利珠单抗组更常见(26% vs 15%),导致阿替利珠单抗/安慰剂中断3% vs 2%,导致退出1% vs 1%。
- 最常见免疫相关不良事件为皮疹(诱导期11% vs 9%,维持期14% vs 4%)和甲状腺功能减退(诱导期4.0% vs 0%,维持期10% vs 1%)。
- 患者报告的功能和健康相关生活质量在两组开始治疗后均改善,阿替利珠单抗组改善更明显且更持久。
临床怎么用
- 对于ES-SCLC患者,一线阿替利珠单抗联合CP/ET方案安全性可控,免疫相关不良事件需重点监测皮疹和甲状腺功能减退。
- 该方案未对患者报告的健康相关生活质量产生不利影响,支持其作为ES-SCLC一线标准治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The addition of atezolizumab to carboplatin and etoposide (CP/ET) significantly improved progression-free and overall survival for patients with extensive-stage small-cell lung cancer (ES-SCLC) in the IMpower133 study (NCT02763579). We have evaluated adverse events (AEs) and patient-reported outcomes in IMpower133 to assess the benefit-risk profile of this regimen. PATIENTS AND METHODS: Patients received four 21-day cycles of CP/ET plus intravenous atezolizumab 1200 mg or placebo (induction phase), followed by atezolizumab or placebo (maintenance phase) until progression or loss of benefit. AEs were assessed and patient-reported outcomes were evaluated every 3 weeks during treatment using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (QLQ-C30) and QLQ-LC13. RESULTS: Overall, 394 patients were assessable for safety in the induction phase and 318 in the maintenance phase. The frequency of AEs, grade 3-4 AEs, and serious AEs was similar between arms in both phases. Immune-related AEs were more frequent in the atezolizumab arm during both induction (28% versus 17%; leading to atezolizumab/placebo interruption 9% versus 5%, leading to withdrawal 4% versus 0%) and maintenance (26% versus 15%; leading to atezolizumab/placebo interruption, 3% versus 2%, leading to withdrawal 1% versus 1%), most commonly rash (induction 11% versus 9%, maintenance 14% versus 4%), and hypothyroidism (induction 4.0% versus 0%, maintenance 10% versus 1%). Changes in patient-reported treatment-related symptoms commonly associated with quality of life impairment were generally similar during induction and most of the maintenance phase. Patient-reported function and health-related quality of life (HRQoL) improved in both arms after initiating treatment, with more pronounced and persistent HRQoL improvements in the atezolizumab arm. CONCLUSIONS: In patients with ES-SCLC, atezolizumab plus CP/ET has a comparable safety profile to placebo plus CP/ET, and the addition of atezolizumab did not adversely impact patient-reported HRQoL. These data demonstrate the positive benefit-risk profile of first-line atezolizumab plus CP/ET in ES-SCLC and further support this regimen as a new standard of care in this setting. CLINICAL TRIALS NUMBER: NCT02763579.
引用
- Mansfield AS, Każarnowicz A, Karaseva N, et al. Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial. Ann Oncol. 2019. PMID: 31959349. doi:10.1016/j.annonc.2019.10.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。